Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Barker

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
The Journal of Allergy and Clinical Immunology|February 20, 2021
Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatmentWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
Advances in Therapy|June 22, 2022
A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab"Andrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
Endocrinology, Diabetes & Metabolism Case Reports|December 23, 2015
Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptidesBenjamin G Challis, Nicolai J Wewer Albrechtsen, Vishakha Bansiya, et al.
Journal of Asthma and Allergy|February 29, 2020
Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)Reynold A Panettieri, Tobias Welte, Kartik V Shenoy, et al.
The Lancet. Respiratory Medicine|May 27, 2017
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trialGary T Ferguson, J Mark FitzGerald, Eugene R Bleecker, et al.
Lancet (London, England)|September 10, 2016
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β<sub>2</sub>-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialEugene R Bleecker, J Mark FitzGerald, Pascal Chanez, et al.
NMR in Biomedicine|September 18, 2020
Spectral editing in <sup>1</sup> H magnetic resonance spectroscopy: Experts' consensus recommendationsIn-Young Choi, Ovidiu C Andronesi, Peter Barker, et al.
The Lancet. Respiratory Medicine|October 3, 2019
Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studiesGerard J Criner, Bartolome R Celli, Dave Singh, et al.
Magnetic Resonance in Medicine|July 5, 2020
Fast whole brain MR imaging of dynamic susceptibility contrast changes in the cerebrospinal fluid (cDSC MRI)Di Cao, Ningdong Kang, Jay J Pillai, et al.
The Journal of Clinical Endocrinology and Metabolism|June 4, 2018
Frequent Monitoring of C-Peptide Levels in Newly Diagnosed Type 1 Subjects Using Dried Blood Spots Collected at HomeRuben H Willemsen, Keith Burling, Peter Barker, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
The Journal of Allergy and Clinical Immunology|February 20, 2021
Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatmentWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
Advances in Therapy|June 22, 2022
A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab"Andrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
Endocrinology, Diabetes & Metabolism Case Reports|December 23, 2015
Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptidesBenjamin G Challis, Nicolai J Wewer Albrechtsen, Vishakha Bansiya, et al.
Journal of Asthma and Allergy|February 29, 2020
Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)Reynold A Panettieri, Tobias Welte, Kartik V Shenoy, et al.
The Lancet. Respiratory Medicine|May 27, 2017
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trialGary T Ferguson, J Mark FitzGerald, Eugene R Bleecker, et al.
Lancet (London, England)|September 10, 2016
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β<sub>2</sub>-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialEugene R Bleecker, J Mark FitzGerald, Pascal Chanez, et al.
NMR in Biomedicine|September 18, 2020
Spectral editing in <sup>1</sup> H magnetic resonance spectroscopy: Experts' consensus recommendationsIn-Young Choi, Ovidiu C Andronesi, Peter Barker, et al.
The Lancet. Respiratory Medicine|October 3, 2019
Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studiesGerard J Criner, Bartolome R Celli, Dave Singh, et al.
Magnetic Resonance in Medicine|July 5, 2020
Fast whole brain MR imaging of dynamic susceptibility contrast changes in the cerebrospinal fluid (cDSC MRI)Di Cao, Ningdong Kang, Jay J Pillai, et al.
The Journal of Clinical Endocrinology and Metabolism|June 4, 2018
Frequent Monitoring of C-Peptide Levels in Newly Diagnosed Type 1 Subjects Using Dried Blood Spots Collected at HomeRuben H Willemsen, Keith Burling, Peter Barker, et al.
Pageof 9